|  |  |  | **Vaccine brand** | | | |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  | **Moderna** | | **Pfizer** | |
|  |  |  | **Exposed** | | | |
| Variable name | Variable level | Estimate name | Unexposed | Exposed | Unexposed | Exposed |
| Number records | - | N | 1,683 | 1,683 | 6,838 | 6,838 |
| Age | - | Median [Q25 - Q75] | 31.00 [27.00 - 35.00] | 31.00 [27.00 - 35.00] | 33.00 [29.00 - 36.00] | 33.00 [29.00 - 36.00] |
| Age group | 12 to 24 | N (%) | 221 (13.1%) | 224 (13.3%) | 691 (10.1%) | 674 (9.9%) |
|  | 25 to 39 | N (%) | 1,368 (81.3%) | 1,373 (81.6%) | 5,490 (80.3%) | 5,506 (80.5%) |
|  | 40 to 55 | N (%) | 94 (5.6%) | 86 (5.1%) | 657 (9.6%) | 658 (9.6%) |
| Vaccine brand | Moderna | N (%) | 1,683 (100.0%) | 1,683 (100.0%) | - | - |
|  | Pfizer | N (%) | - | - | 6,838 (100.0%) | 6,838 (100.0%) |
| Trimester | Trimester 1 | N (%) | 519 (30.8%) | 514 (30.5%) | 1,680 (24.6%) | 1,687 (24.7%) |
|  | Trimester 2 | N (%) | 657 (39.0%) | 645 (38.3%) | 2,844 (41.6%) | 2,817 (41.2%) |
|  | Trimester 3 | N (%) | 507 (30.1%) | 524 (31.1%) | 2,314 (33.8%) | 2,334 (34.1%) |
| Number visits prior year | - | Median [Q25 - Q75] | 16.00 [8.00 - 29.00] | 30.00 [16.00 - 50.00] | 17.00 [9.00 - 30.00] | 32.00 [18.00 - 54.00] |
| Number prior pregnancies | - | Median [Q25 - Q75] | 1.00 [1.00 - 1.00] | 2.00 [2.00 - 2.00] | 1.00 [1.00 - 1.00] | 2.00 [2.00 - 2.00] |
| Conditions any time prior | Anemia | N (%) | 441 (26.2%) | 386 (22.9%) | 1,689 (24.7%) | 1,521 (22.2%) |
|  | Heart conditions | N (%) | 35 (2.1%) | 37 (2.2%) | 130 (1.9%) | 170 (2.5%) |
|  | Eclampsia preeclampsia | N (%) | 26 (1.5%) | 23 (1.4%) | 78 (1.1%) | 71 (1.0%) |
|  | Asthma | N (%) | 98 (5.8%) | 109 (6.5%) | 375 (5.5%) | 414 (6.1%) |
|  | Pneumonia | N (%) | 48 (2.9%) | 63 (3.7%) | 199 (2.9%) | 221 (3.2%) |
|  | Hypothyroidism | N (%) | 109 (6.5%) | 133 (7.9%) | 557 (8.1%) | 620 (9.1%) |
|  | Depressive disorder | N (%) | 90 (5.3%) | 93 (5.5%) | 368 (5.4%) | 400 (5.8%) |
|  | Gestational diabetes | N (%) | 84 (5.0%) | 88 (5.2%) | 419 (6.1%) | 413 (6.0%) |
|  | Chronic hypertension | N (%) | 45 (2.7%) | 40 (2.4%) | 162 (2.4%) | 161 (2.4%) |
|  | Anxiety disorder | N (%) | 458 (27.2%) | 449 (26.7%) | 1,870 (27.3%) | 1,899 (27.8%) |
|  | Chronic obstructive lung disease | N (%) | 0 (0.0%) | <5 (<5%) | <5 (<5%) | 9 (0.1%) |
| Drugs prior 180 days | Propulsives | N (%) | 67 (4.0%) | 78 (4.6%) | 274 (4.0%) | 264 (3.9%) |
|  | Progestogens | N (%) | 71 (4.2%) | 92 (5.5%) | 404 (5.9%) | 365 (5.3%) |
|  | Antimycotics systemic | N (%) | 6 (0.4%) | 10 (0.6%) | 31 (0.5%) | 36 (0.5%) |
|  | Estrogens | N (%) | 123 (7.3%) | 113 (6.7%) | 497 (7.3%) | 490 (7.2%) |
|  | Antithrombotics | N (%) | 134 (8.0%) | 79 (4.7%) | 379 (5.5%) | 304 (4.4%) |
|  | Antihistamines systemic | N (%) | 242 (14.4%) | 288 (17.1%) | 1,014 (14.8%) | 1,057 (15.5%) |
|  | Antidepressants | N (%) | 88 (5.2%) | 84 (5.0%) | 288 (4.2%) | 377 (5.5%) |
|  | Immunoglobulins | N (%) | 67 (4.0%) | 49 (2.9%) | 295 (4.3%) | 286 (4.2%) |
|  | Analgesics and antipyretics | N (%) | 622 (37.0%) | 581 (34.5%) | 2,300 (33.6%) | 2,334 (34.1%) |
|  | Antiinflammatory antirehumatic | N (%) | 263 (15.6%) | 279 (16.6%) | 1,010 (14.8%) | 1,011 (14.8%) |
|  | Antiepileptics | N (%) | 27 (1.6%) | 41 (2.4%) | 96 (1.4%) | 99 (1.4%) |
|  | Antibacterials systemic | N (%) | 418 (24.8%) | 413 (24.5%) | 1,582 (23.1%) | 1,578 (23.1%) |